Lv3
350 积分 2021-10-21 加入
Managing toxicities of high-dose interleukin-2
13天前
已关闭
Managing toxicities of high-dose interleukin-2
13天前
已关闭
Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma
1个月前
已完结
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
2个月前
已完结
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
2个月前
已完结
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
3个月前
已完结
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
3个月前
已完结
A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
3个月前
已完结
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
4个月前
已完结
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma
4个月前
已完结
皖公网安备34019202002308
